Literature DB >> 29492257

Alternatives to ketamine in depression: state-of-the-art and future perspectives.

Luke A Jelen1, Sinead King2, James M Stone3.   

Abstract

Entities:  

Year:  2017        PMID: 29492257      PMCID: PMC5802640          DOI: 10.1177/2045125317749456

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


× No keyword cloud information.
  21 in total

1.  A double-blind, placebo-controlled study of memantine in the treatment of major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Jorge A Quiroz; Georgette De Jesus; Kirk K Denicoff; David A Luckenbaugh; Husseini K Manji; Dennis S Charney
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Do the dissociative side effects of ketamine mediate its antidepressant effects?

Authors:  David A Luckenbaugh; Mark J Niciu; Dawn F Ionescu; Neal M Nolan; Erica M Richards; Nancy E Brutsche; Sara Guevara; Carlos A Zarate
Journal:  J Affect Disord       Date:  2014-02-18       Impact factor: 4.839

3.  Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.

Authors:  Peter Nagele; Andreas Duma; Michael Kopec; Marie Anne Gebara; Alireza Parsoei; Marie Walker; Alvin Janski; Vassilis N Panagopoulos; Pilar Cristancho; J Philip Miller; Charles F Zorumski; Charles R Conway
Journal:  Biol Psychiatry       Date:  2014-12-09       Impact factor: 13.382

4.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

5.  Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.

Authors:  Erinn S Gideons; Ege T Kavalali; Lisa M Monteggia
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

6.  Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.

Authors:  Jaskaran B Singh; Maggie Fedgchin; Ella Daly; Liwen Xi; Caroline Melman; Geert De Bruecker; Andre Tadic; Pascal Sienaert; Frank Wiegand; Husseini Manji; Wayne C Drevets; Luc Van Nueten
Journal:  Biol Psychiatry       Date:  2015-11-03       Impact factor: 13.382

7.  A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.

Authors:  Uriel Heresco-Levy; Genia Gelfin; Boaz Bloch; Raz Levin; Shani Edelman; Daniel C Javitt; Ilana Kremer
Journal:  Int J Neuropsychopharmacol       Date:  2012-09-17       Impact factor: 5.176

8.  GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Authors:  Jeffrey Burgdorf; Xiao-lei Zhang; Katherine L Nicholson; Robert L Balster; J David Leander; Patric K Stanton; Amanda L Gross; Roger A Kroes; Joseph R Moskal
Journal:  Neuropsychopharmacology       Date:  2012-12-05       Impact factor: 7.853

9.  An open-label, flexible-dose study of memantine in major depressive disorder.

Authors:  James M Ferguson; Richard N Shingleton
Journal:  Clin Neuropharmacol       Date:  2007 May-Jun       Impact factor: 1.592

10.  Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

Authors:  Graham L Collingridge; Yeseul Lee; Zuner A Bortolotto; Heather Kang; David Lodge
Journal:  Biol Psychiatry       Date:  2016-09-28       Impact factor: 13.382

View more
  5 in total

1.  Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice.

Authors:  Priyodarshan Goswamee; Remington Rice; Elizabeth Leggett; Fan Zhang; Sofia Manicka; Joseph H Porter; A Rory McQuiston
Journal:  Neuropharmacology       Date:  2022-01-20       Impact factor: 5.250

2.  An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression.

Authors:  Sherry-Anne Muscat; Glenn Hartelius; Courtenay Richards Crouch; Kevin W Morin
Journal:  Front Psychiatry       Date:  2021-11-24       Impact factor: 4.157

3.  Suicidal behavior-advances in clinical and neurobiological research and improvement of prevention strategies.

Authors:  Thomas Sobanski; Gregor Peikert; Ulrich W Kastner; Gerd Wagner
Journal:  World J Psychiatry       Date:  2022-09-19

Review 4.  Neuronal nitric oxide synthase and affective disorders.

Authors:  Qi-Gang Zhou; Xian-Hui Zhu; Ashley D Nemes; Dong-Ya Zhu
Journal:  IBRO Rep       Date:  2018-11-17

5.  Ketamine: A tale of two enantiomers.

Authors:  Luke A Jelen; Allan H Young; James M Stone
Journal:  J Psychopharmacol       Date:  2020-11-06       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.